The findings in a recent phase 3 clinical study may allow Kalvista Pharma to seek FDA approval for this potential hereditary angioedema treatment option.
KalVista Pharmaceuticals, Inc. , today announced that the compensation committee of KalVista’s board of directors granted three newly-hired employees inducement options to purchase an aggregate. | June 5, 2023
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista's board of directors granted three newly-hired employees inducement options to purchase an aggregate
KalVista Pharmaceuticals, Inc. , a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it. | May 31, 2023
KalVista Pharmaceuticals, Inc. , a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it. | May 23, 2023